## Granules India Limited (GRANULES) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Granules India Limited (GRANULES) is a pharmaceutical company listed on the NSE (National Stock Exchange of India) on June 20, 2005.  It operates within the Pharmaceuticals & Biotechnology industry, focusing on the manufacturing and supply of pharmaceutical products.  The company's exact positioning within the sector requires further research beyond the provided data, but its presence on the NSE suggests a significant market share within India.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹591            |  Down ₹9.05 (-1.51%) from the previous close.                       |
| Percentage Change (PChange) | -1.51%          | Negative change indicates a downward trend in the current session. |
| Pre-Open Activity          | ₹602.5 (0.41%)  | Positive pre-open activity, but the current price is lower.       |
| Week High                    | ₹721 (30-Aug-2024) | Significant high suggests potential for upward movement.           |
| Week Low                     | ₹365.45 (21-Dec-2023) | Significant low indicates considerable volatility.                   |
| VWAP                        | ₹601.03         | Volume Weighted Average Price slightly above the current price.     |
| Sector PE                   | 29.87           | Industry average Price-to-Earnings ratio.                          |
| Symbol PE                   | 29.87           | GRANULES' Price-to-Earnings ratio, in line with the sector average.|
| Delivery Percentage         | 52.61%          | Relatively high delivery percentage suggests some institutional interest.|
| Market Depth                | Low              |  Order book data shows low market depth (total buy/sell quantity is 0). This suggests low liquidity. |


**3. Financial Performance:**

The provided financial data shows a consistent profit after tax (PAT) and earnings per share (EPS) over the past five quarters, although the figures are unaudited for the most recent two quarters.  However, there's a notable decline in PAT and EPS from Q4 2023 to Q2 2024.  Further analysis is needed to determine the cause of this decline.

| Quarter      | Revenue (₹) | Expenditure (₹) | Profit After Tax (₹) | EPS (₹) |
|--------------|--------------|-------------------|-----------------------|---------|
| Q1 2024      | 94,361.6     | 80,710.5          | 9,721.6               | 4.01    |
| Q2 2024      | 85,375.8     | 72,789.9          | 9,377.9               | 3.87    |
| Q3 2024      | 57,077.1     | 51,469.7          | 4,139.2               | 1.71    |
| Q4 2023      | 98,515.1     | 79,353.9          | 14,270.5              | 5.89    |
| Q3 2023      | 101,066.5    | 85,465.2          | 11,615.7              | 4.80    |


**Key Financial Ratios:**  Further analysis is needed to calculate and interpret key ratios like Return on Equity (ROE), Debt-to-Equity ratio, and Profit Margin using the provided data.  The available data only provides a snapshot of revenue, expenditure, PAT, and EPS.

**4. Corporate Actions and Announcements:**

Recent corporate actions include dividend payments (most recently ₹1.50 per share with an ex-date of July 30, 2024) and previous buyback announcements.  Several announcements regarding loss of share certificates and changes in management/personnel have been made.  These announcements, while not directly impacting the stock price in a predictable way, highlight potential governance issues that warrant further investigation.

**5. Shareholding Patterns:**

| Quarter      | Promoter & Promoter Group (%) | Public (%) | Shares held by Employee Trusts (%) | Total (%) |
|--------------|-----------------------------|------------|---------------------------------|-----------|
| 30-Sep-2023  | 41.96                        | 58.04      | 0.00                           | 100.00    |
| 31-Dec-2023  | 41.96                        | 58.04      | 0.00                           | 100.00    |
| 31-Mar-2024  | 41.96                        | 58.04      | 0.00                           | 100.00    |
| 30-Jun-2024  | 38.87                        | 61.13      | 0.00                           | 100.00    |
| 30-Sep-2024  | 38.87                        | 61.13      | 0.00                           | 100.00    |

A significant decrease in promoter holding from approximately 42% to 39% between June 2024 and September 2024 is observed. This warrants further investigation into the reasons behind this reduction.

**6. Volatility and Risk Assessment:**

The stock exhibits high volatility, as evidenced by the week's high and low prices.  The CM Annual Volatility of 48.14% further confirms this.  The low market depth adds to the risk, making it difficult to execute large trades without significantly impacting the price.  The risk-reward profile is currently skewed towards risk due to the volatility and recent decline in financial performance.

**7. Advantages of Buying the Stock:**

* Consistent dividend payouts.
* Presence in a growing pharmaceutical sector.


**8. Disadvantages and Risks:**

* High volatility.
* Recent decline in financial performance (Q3 2024).
* Low market depth (liquidity risk).
* Decrease in promoter holding.
* Several announcements regarding loss of share certificates and changes in management raise governance concerns.


**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Don't Buy.** The current downward price momentum, high volatility, and low market depth make a short-term investment risky.  The recent decline in financial performance also adds to the risk.

* **Medium-term (3 to 12 months): Hold (if you have stock).**  A medium-term outlook requires monitoring the company's financial performance and addressing the concerns raised by the decrease in promoter holding and the numerous announcements.  If the company can demonstrate a turnaround in its financial performance and address governance concerns, the medium-term outlook could improve.

* **Long-term (1 year and beyond): Don't Buy.**  While the pharmaceutical sector offers long-term growth potential, the current risks associated with GRANULES, including volatility, declining financial metrics, and governance concerns, outweigh the potential benefits for a long-term investment.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 5.5**

* Financial health: 6/10 (Consistent profitability in the past, but recent decline is concerning)
* Market performance: 4/10 (High volatility, negative recent price movement)
* Volatility and risk: 3/10 (High volatility, low liquidity)
* Corporate actions and governance: 5/10 (Consistent dividends, but governance concerns need addressing)
* Shareholding patterns: 4/10 (Significant decrease in promoter holding)

**Analysis Score (out of 10): 8/10**

* Completeness and utilization of all provided data: 9/10 (Most data points were used effectively)
* Accuracy and clarity of the analysis: 8/10 (Analysis is clear, but some assumptions were made due to incomplete data)
* Professional formatting: 9/10 (Report is well-structured and easy to read)


**11. Professional Recommendation Summary:**

Based on the analysis of the provided data, GRANULES is not recommended for short-term or long-term investment.  If an investor already holds the stock, a "Hold" strategy is suggested for the medium term, contingent upon close monitoring of the company's financial performance and resolution of governance concerns.  Further investigation into the reasons behind the decline in financial performance and the decrease in promoter holding is crucial before making any investment decision.  The high volatility and low liquidity also present significant risks.
